The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis
The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial
Sponsor: Sadat City University
Listed as NCT04080947, this PHASE1/PHASE2 trial focuses on Steatohepatitis, Nonalcoholic and remains completed. Sponsored by Sadat City University, it has been updated 12 times since 2019, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Oct 2021 — Mar 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Withdrawn → Active Not Recruiting · Phase: EARLY_PHASE1 → PHASE1_PHASE2
-
Mar 2021 — Apr 2021 [monthly]
Withdrawn EARLY_PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Withdrawn EARLY_PHASE1
-
May 2020 — Jan 2021 [monthly]
Withdrawn EARLY_PHASE1
-
Mar 2020 — May 2020 [monthly]
Withdrawn EARLY_PHASE1
Status: Recruiting → Withdrawn
-
Oct 2019 — Mar 2020 [monthly]
Recruiting EARLY_PHASE1
First recorded
Aug 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sadat City University
For direct contact, visit the study record on ClinicalTrials.gov .